A genetic polymorphism of CYP2C19 is associated with susceptibility to biliary tract cancer

Journal of Gastroenterology

Volumn 45, Issue 10, 2010, Pages 1045-1052

  Isomura, Yoshihiro ^a   Yamaji, Yutaka ^a   Ohta, Miki ^b   Seto, Motoko ^a   Asaoka, Yoshinari ^a   Tanaka, Yasuo ^a   Sasaki, Takashi ^a   Nakai, Yousuke ^a   Sasahira, Naoki ^a   Isayama, Hiroyuki ^a   Tada, Minoru ^a   Yoshida, Haruhiko ^a   Kawabe, Takao ^a   Omata, Masao ^c   Koike, Kazuhiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b FUKUOKA SANNO HOSPITAL   (Japan)

^c Yamanashi Prefectural Central Hospital   (Japan)

Author keywords

Biliary tract cancer; CYP2C19; Genetic polymorphism

Indexed keywords

CYTOCHROME P450 2C19;

ADULT; ARTICLE; BILIARY TRACT CANCER; CANCER CELL CULTURE; CANCER SCREENING; CANCER SUSCEPTIBILITY; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LIVER CANCER; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PRIORITY JOURNAL; STOMACH CANCER;

ADULT; AGED; ARYL HYDROCARBON HYDROXYLASES; BILIARY TRACT NEOPLASMS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; DIGESTIVE SYSTEM NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 78249270407     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-010-0246-0     Document Type: Article

References (39)

1. Chiba K, Kobayashi K, Manabe K, Tani M, Kamataki T, Ishizaki T. Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4′-hydroxylation. J Pharmacol Exp Ther. 1993;266:52-9.
2. Ishizaki T, Sohn DR, Kobayashi K, Chiba K, Lee KH, Shin SG, et al. Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. Ther Drug Monit. 1994;16:214-5.
3. I Ieiri T Kubota A Urae M Kimura Y Wada K Mamiya, et al. 1996 Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, C gamma P2C19m1 in exon 5 and C gamma P2C19m2 in exon 4, in Japanese subjects Clin Pharmacol Ther 59 647 653 1:CAS:528:DyaK28XksFemurc%3D 10.1016/S0009-9236(96)90004-1 8681489 (Pubitemid 26233420)
4. Bertilsson L, Henthorn TK, Sanz E, Tybring G, Sawe J, Villen T. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther. 1989;45:348-55.
5. E Skjelbo K Brosen J Hallas LF Gram 1991 The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine Clin Pharmacol Ther 49 18 23 1:STN:280:DyaK3M7gs1Sntw%3D%3D 10.1038/clpt.1991.4 1988236
6. SA Ward T Walle UK Walle GR Wilkinson RA Branch 1989 Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities Clin Pharmacol Ther 45 72 79 1:CAS:528:DyaL1MXht1OqtLk%3D 10.1038/clpt.1989.11 2910639
7. Kobayashi K, Yamamoto T, Chiba K, Tani M, Ishizaki T, Kuroiwa Y. The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4′-hydroxylase activity in human liver microsomes. Br J Clin Pharmacol. 1995;40:481-5.
8. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009;373:309-17.
9. JL Mega SL Close SD Wiviott L Shen RD Hockett JT Brandt, et al. 2009 Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 354 362 1:CAS:528:DC%2BD1MXhtVSlsbs%3D 10.1056/NEJMoa0809171 19106084
10. Kubota T, Chiba K, Ishizaki T. Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin Pharmacol Ther. 1996;60:661-6.
11. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol. 1994;46:594-8. (Pubitemid 24334747)
12. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 1994;269:15419-22.
13. T Furuta K Ohashi K Kosuge XJ Zhao M Takashima M Kimura, et al. 1999 CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans Clin Pharmacol Ther 65 552 561 1:CAS:528:DyaK1MXjslSrtrk%3D 10.1016/S0009- 9236(99)70075-5 10340921 (Pubitemid 29237329)
14. U Klotz 2006 Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem Int J Clin Pharmacol Ther 44 297 302 1:CAS:528:DC%2BD28XovF2gtLc%3D 16961157
15. T Furuta K Ohashi T Kamata M Takashima K Kosuge T Kawasaki, et al. 1998 Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer Ann Intern Med 129 1027 1030 1:STN:280:DyaK1M%2FmsVyntg%3D%3D 9867757
16. SM Jeurissen JJ Bogaards MG Boersma JP ter Horst HM Awad YC Fiamegos, et al. 2006 Human cytochrome p450 enzymes of importance for the bioactivation of methyleugenol to the proximate carcinogen 1′-hydroxymethyleugenol Chem Res Toxicol 19 111 116 1:CAS:528:DC%2BD2MXhtlarsLrP 10.1021/tx050267h 16411663 (Pubitemid 43185468)
17. M Degawa 1995 Chemical carcinogenesis and cytochrome P450: carcinogenic aromatic amine-induced P450 and hepatocarcinogenic susceptibility to the aromatic amine in the rodent Yakugaku Zasshi 115 1 14 1:CAS:528: DyaK2MXktlKgur0%3D 7699577
18. WX Shi SQ Chen 2004 Frequencies of poor metabolizers of cytochrome P450 2C19 in esophagus cancer, stomach cancer, lung cancer and bladder cancer in Chinese population World J Gastroenterol 10 1961 1963 1:CAS:528: DC%2BD2cXmslWrtbw%3D 15222046
19. PL Roddam S Rollinson E Kane E Roman A Moorman R Cartwright, et al. 2000 Poor metabolizers at the cytochrome P450 2D6 and 2C19 loci are at increased risk of developing adult acute leukaemia Pharmacogenetics 10 605 615 1:CAS:528:DC%2BD3cXnsFCrtbg%3D 10.1097/00008571-200010000-00004 11037802
20. M Sugimoto T Furuta N Shirai A Nakamura M Kajimura H Sugimura, et al. 2005 Poor metabolizer genotype status of CYP2C19 is a risk factor for developing gastric cancer in Japanese patients with Helicobacter pylori infection Aliment Pharmacol Ther 22 1033 1040 1:CAS:528:DC%2BD2MXhtlWntrrJ 10.1111/j.1365-2036. 2005.02678.x 16268979 (Pubitemid 41634886)
21. M Nagahashi Y Ajioka I Lang Z Szentirmay M Kasler H Nakadaira, et al. 2008 Genetic changes of p53, K-ras, and microsatellite instability in gallbladder carcinoma in high-incidence areas of Japan and Hungary World J Gastroenterol 14 70 75 1:CAS:528:DC%2BD1cXjsFykt7s%3D 10.3748/wjg.14.70 18176964 (Pubitemid 351314329)
22. M Yamamoto M Haga S Takagi K Endoh S Ito K Yoshida, et al. 1990 HLA antigens in cancer of the gallbladder Tohoku J Exp Med 161 69 71 1:STN:280:DyaK3czntFGmsg%3D%3D 10.1620/tjem.161.69 2396258
23. S Sheth A Bedford S Chopra 2000 Primary gallbladder cancer: recognition of risk factors and the role of prophylactic cholecystectomy Am J Gastroenterol 95 1402 1410 1:STN:280:DC%2BD3czltFSluw%3D%3D 10.1111/j.1572-0241.2000.02070.x 10894571
24. WHO (2006) Mortality database. http://www.who.int/healthinfo/morttables/ en/index.html
25. I Serra M Yamamoto A Calvo G Cavada S Baez K Endoh, et al. 2002 Association of chili pepper consumption, low socioeconomic status and longstanding gallstones with gallbladder cancer in a Chilean population Int J Cancer 102 407 411 1:CAS:528:DC%2BD38Xos1ajtb0%3D 10.1002/ijc.10716 12402311 (Pubitemid 35265881)
26. Xie HG. Genetic variations of S-mephenytoin 4′-hydroxylase (CYP2C19) in the Chinese population. Life Sci. 2000;66:PL175-81.
27. HG Xie RB Kim CM Stein GR Wilkinson AJ Wood 1999 Genetic polymorphism of (S)-mephenytoin 4′-hydroxylation in populations of African descent Br J Clin Pharmacol 48 402 408 1:CAS:528:DyaK1MXmsFehsLs%3D 10.1046/j.1365-2125.1999. 00009.x 10510153 (Pubitemid 29417725)
28. S Yamamoto 2000 Biliary tract cancer mortality rates by prefectures in Japan Jpn J Clin Oncol 30 576 1:STN:280:DC%2BD3M7hvFyntg%3D%3D 11210170
29. Y Adachi 1994 Changes in the concentrations of chlornitrofen (CNP) and CNP-amino in river and faucet water in Niigata, Japan Nippon Eiseigaku Zasshi 48 1090 1098 1:CAS:528:DyaK2cXisl2nt7o%3D 8126930
30. K Kawajiri K Nakachi K Imai A Yoshii N Shinoda J Watanabe 1990 Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene FEBS Lett 263 131 133 1:CAS:528:DyaK3cXitleiu74%3D 10.1016/0014-5793(90)80721-T 1691986 (Pubitemid 20107795)
31. N Drakoulis I Cascorbi J Brockmoller CR Gross I Roots 1994 Polymorphisms in the human CYP1A1 gene as susceptibility factors for lung cancer: exon-7 mutation (4889 A to G), and a T to C mutation in the 3′-flanking region Clin Investig 72 240 248 1:CAS:528:DyaK2MXhslGisQ%3D%3D 10.1007/BF00189321 7912124
32. X Shi S Zhou Z Wang Z Zhou 2008 CYP1A1 and GSTM1 polymorphisms and lung cancer risk in Chinese populations: a meta-analysis Lung Cancer 59 155 163 10.1016/j.lungcan.2007.08.004 17900751 (Pubitemid 351173406)
33. F Uematsu S Ikawa H Kikuchi I Sagami R Kanamaru T Abe, et al. 1994 Restriction fragment length polymorphism of the human CYP2E1 (cytochrome P450IIE1) gene and susceptibility to lung cancer: possible relevance to low smoking exposure Pharmacogenetics 4 58 63 1:CAS:528:DyaK2MXjsVKjsg%3D%3D 10.1097/00008571-199404000-00002 7915935
34. D Aktas I Guney M Alikasifoglu K Yuce E Tuncbilek A Ayhan 2002 CYP1A1 gene polymorphism and risk of epithelial ovarian neoplasm Gynecol Oncol 86 124 128 1:CAS:528:DC%2BD38XlsFKgtLo%3D 10.1006/gyno.2002.6720 12144816 (Pubitemid 34953492)
35. Y Nimura S Yokoyama M Fujimori T Aoki W Adachi T Nasu, et al. 1997 Genotyping of the CYP1A1 and GSTM1 genes in esophageal carcinoma patients with special reference to smoking Cancer 80 852 857 1:STN:280:DyaK2svltVOnsA%3D%3D 10.1002/(SICI)1097-0142(19970901)80:5<852::AID-CNCR4>3.0.CO;2-N 9307183 (Pubitemid 27360465)
36. DX Lin YM Tang Q Peng SX Lu CB Ambrosone FF Kadlubar 1998 Susceptibility to esophageal cancer and genetic polymorphisms in glutathione S-transferases T1, P1, and M1 and cytochrome P450 2E1 Cancer Epidemiol Biomarkers Prev 7 1013 1018 1:CAS:528:DyaK1cXns1ektbs%3D 9829710
37. M Murata M Watanabe M Yamanaka Y Kubota H Ito M Nagao, et al. 2001 Genetic polymorphisms in cytochrome P450 (CYP) 1A1, CYP1A2, CYP2E1, glutathione S-transferase (GST) M1 and GSTT1 and susceptibility to prostate cancer in the Japanese population Cancer Lett 165 171 177 1:CAS:528:DC%2BD3MXitF2ru7g%3D 10.1016/S0304-3835(01)00398-6 11275366 (Pubitemid 32244174)
38. SI Hayashi J Watanabe K Nakachi K Kawajiri 1991 PCR detection of an A/G polymorphism within exon 7 of the CYP1A1 gene Nucleic Acids Res 19 4797 1:CAS:528:DyaK3MXmtVShsro%3D 10.1093/nar/19.17.4797 1891387
39. LL Marchand GR Wilkinson LR Wilkens 1999 Genetic and dietary predictors of CYP2E1 activity: a phenotyping study in Hawaii Japanese using chlorzoxazone Cancer Epidemiol Biomarkers Prev 8 495 500 1:STN:280:DyaK1MzhtFyltg%3D%3D 10385138